J&J’s AI head jumps to Recursion; Doug Williams resigns as Sana’s R&D chief

Re­cur­sion Phar­ma­ceu­ti­cals has poached Na­jat Khan from John­son & John­son, where she led AI ef­forts at one of health­care’s gi­ants.

Khan will serve as chief R&D and com­mer­cial of­fi­cer, along with join­ing Re­cur­sion’s board. The move comes at a crit­i­cal time for Re­cur­sion, as its stock price has fall­en 75% since go­ing pub­lic in 2021, cur­rent­ly com­mand­ing a mar­ket cap­i­tal­iza­tion of $1.75 bil­lion. The Utah biotech ex­pects its first Phase 2 read­outs lat­er this year for two rare dis­ease drug can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.